Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Manpenkang is a Traditional Chinese Medicine (TCM) formulation developed by Shaanxi Jingwei Group Co., Ltd. for the treatment of chronic pelvic pain and sequelae of pelvic inflammatory disease (PID). It is specifically designed to address the TCM syndrome of damp-heat and blood stasis (湿热瘀毒蕴结证). The drug is formulated as an enema solution, allowing for rectal administration to facilitate local absorption and therapeutic action within the pelvic cavity. Clinical evaluation, including the Phase III trial CTR20140224 in China, has focused on assessing its safety and efficacy in alleviating chronic pelvic symptoms compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Manpenkang.